https://www.businesswire.com/news/home/20190808005189/en/

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug 8, 2019--

Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, today reported financial results for the second quarter ended June 30, 2019 and recent business highlights.